NasdaqGS:CERTHealthcare Services
Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches
Certara (CERT) is back on investors’ radar after closing 2025 with revenue of US$418.8m, a small net loss, and fresh FDA validation of its biosimulation platform through PBPK modeling used in the asciminib NDA.
See our latest analysis for Certara.
Despite FDA validation for its PBPK work and new software launches, Certara’s share price has been under pressure, with a 90 day share price return of 23.91% and a 1 year total shareholder return of 39.10%. This may indicate fading momentum after...